Pharma Focus Asia
KP - Sustainable Packaging Solutions

Marker Therapeutics Plans to Construct New Manufacturing Facility in Texas


Marker Therapeutics plans to construct a new manufacturing facility to support clinical development of MultiTAA-Specific T cell therapy product candidates. The new location will be constructed at Houston, TX, nearby George Bush Intercontinental Airport.


The new facility is designed with sufficient space to undergo clinical manufacturing and quality functions covering an area of 48,500 feet.

The construction of new internal manufacturing capabilities provides the opportunity of conducting AML trials, and future hematological and solid tumor trials, as well as the potential commercialisation of products.

The manufacturing of MultiTAA-specific T cell therapy at the Baylor College of Medicine continues to support AML trials until the newly built in-house cGMP manufacturing facility is fully operational.

The new manufacturing facility is expected to be completed by the end of 2020 and fully operational in 2021.


NameMarker Therapeutics, Inc
TypeNew Construction
Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024Gibco Adherent Kidney Media PanelTFS - ODW - The Technology Debate: Single-Use vs. Stainless SteelAsia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 20244th Middle East Pharmacoeconomics and Drug Policy Summit 2024Digital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference
Searching for an end-to-end patient tech solution?